JAGUAR HEALTH, INC. Lease Obligation Incurred
JAGUAR HEALTH, INC. (JAGX) reported Lease Obligation Incurred of $441.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2025-03-31
- JAGUAR HEALTH, INC. lease obligation incurred for fiscal 2023 was $441.00K.
- JAGUAR HEALTH, INC. lease obligation incurred for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- JAGUAR HEALTH, INC. lease obligation incurred for fiscal 2021 was $91.00K.
- JAGUAR HEALTH, INC. lease obligation incurred for fiscal 2020 was $0.00.
| Period end | Lease Obligation Incurred 12 month | Lease Obligation Incurred 12 month as first filed |
|---|---|---|
| 2023-12-31 | $441.00K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 | |
| 2021-12-31 | $91.00K 10-K · filed 2023-03-24 | $91.24K 10-K · filed 2022-03-11 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |